Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

A near complete skull fossil found in Antarctica has revealed the oldest known modern bird — a mallard duck-size creature related to the waterfowl that live by lakes and oceans today ...

It can be tricky to pinpoint the cause of pain at the base of your skull, the area behind your ears where your head and neck meet. Understanding the cause of the pain can help you determine how to ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Landmark Immigration Consultants IPO, opened for subscription on Thursday, January 16. The ₹40.32 crore book-built issue is garnering a strong response from investors. The grey market premium ...

courtesy Mariia Zelenina While floating underwater before cheerful children and other park guests, things quickly took a turn when one of the larger fish suddenly inhaled her head. Zelenina ...

Excalidraw is an innovative online whiteboarding tool that uses the power of artificial intelligence (AI) to convert simple text prompts into detailed, professional-quality diagrams. Whether you ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Landmark Immigration IPO Allotment: The allotment for Landmark Immigration IPO is expected to be finalised today, January 21. Investors can check their allotment status through the registrar, Kfin ...

Images captured before the Southern California wildfires of a deserted surfer's resort, sculpture at the Bunny Museum and the ranch house at the Will Rogers State Historic Park. (Getty Images ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...